enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) rose 6.4% on Thursday . The company traded as high as $3.85 and last traded at $3.82. Approximately 137,510 shares changed hands during mid-day trading, an increase of 24% from the average daily volume of 111,185 shares. The stock had previously closed at $3.59.
enVVeno Medical Stock Up 6.4 %
The stock's 50-day moving average price is $3.19 and its 200-day moving average price is $3.76. The company has a market capitalization of $66.99 million, a price-to-earnings ratio of -2.96 and a beta of 1.22.
Institutional Investors Weigh In On enVVeno Medical
A number of institutional investors and hedge funds have recently made changes to their positions in NVNO. Westside Investment Management Inc. grew its holdings in enVVeno Medical by 132.0% during the 4th quarter. Westside Investment Management Inc. now owns 205,025 shares of the company's stock worth $619,000 after acquiring an additional 116,650 shares during the period. Geode Capital Management LLC boosted its position in shares of enVVeno Medical by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company's stock worth $506,000 after purchasing an additional 10,902 shares during the last quarter. Fermata Advisors LLC grew its stake in shares of enVVeno Medical by 18.1% during the fourth quarter. Fermata Advisors LLC now owns 35,706 shares of the company's stock worth $108,000 after purchasing an additional 5,481 shares during the period. Hohimer Wealth Management LLC bought a new stake in enVVeno Medical in the third quarter valued at about $286,000. Finally, Maven Securities LTD acquired a new position in enVVeno Medical in the third quarter valued at about $295,000. Institutional investors own 34.71% of the company's stock.
enVVeno Medical Company Profile
(
Get Free Report)
enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enVVeno Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enVVeno Medical wasn't on the list.
While enVVeno Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
